title: Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.
abstract: OBJECTIVE
  This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT).
  
  
  METHODS
  Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT.
  
  
  RESULTS
  With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively).
  
  
  CONCLUSIONS
  We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.
authors.affiliation: Centre Hospitalier Universitaire (CHU) Hôtel-Dieu, Cellule de Promotion à la Recherche Clinique, CHU Hotel-Dieu, Nantes, France. patrice.chevallier@chu-nantes.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Chevallier
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Bruno
authors.initials: B
authors.lastname: Lioure
authors.forename: Gerard
authors.initials: G
authors.lastname: Michel
authors.forename: Nathalie
authors.initials: N
authors.lastname: Contentin
authors.forename: Eric
authors.initials: E
authors.lastname: Deconinck
authors.forename: Pierre
authors.initials: P
authors.lastname: Bordigoni
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Vernant
authors.forename: Mathilde
authors.initials: M
authors.lastname: Hunault
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vigouroux
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizi
authors.forename: Agnes
authors.initials: A
authors.lastname: Buzyn
authors.forename: Gerard
authors.initials: G
authors.lastname: Socie
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Christelle
authors.initials: C
authors.lastname: Volteau
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D023981:Sarcoma, Myeloid / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome